Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: Synthesis, absolute configuration, and in vitro activity

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4226-4238

  Wood, Paul M ^a   Woo, L W Lawrence ^a   Labrosse, Jean Robert ^a   Trusselle, Melanie N ^a   Abbate, Sergio ^b   Longhi, Giovanna ^b   Castiglioni, Ettore ^b,c   Lebon, France ^b   Purohit, Atul ^d   Reed, Michael J ^d   Potter, Barry V L ^a  

^a UNIVERSITY OF BATH   (United Kingdom)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Hachioji shi   (Japan)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(4 CYANOPHENYL)(3 BROMO 4 HYDROXYPHENYL)METHYL] 1H [1,2,4]TRIAZOLE; 1 [(4 CYANOPHENYL)(3 BROMO 4 SULFAMOYLOXYPHENYL)METHYL] 1H [1,2,4]TRIAZOLE; AROMATASE; AROMATASE INHIBITOR; DUAL AROMATASE STEROID SULFATASE INHIBITOR; LETROZOLE; PHENOL DERIVATIVE; STX 64; SULFUR DERIVATIVE; VOROZOLE;

ARTICLE; BREAST CANCER; CHIRALITY; CIRCULAR DICHROISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHARMACOPHORE; SEPARATION TECHNIQUE; STRUCTURE ACTIVITY RELATION;

AROMATASE; AROMATASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; HUMANS; MOLECULAR STRUCTURE; NITRILES; STEREOISOMERISM; STERYL-SULFATASE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 47749151848     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800168s     Document Type: Article

References (62)

1. Brodie, A. Aromatase inhibitors in breast cancer. Trends Endocrinol. Metab. 2002, 13, 61-65.
2. Recanatini, M.; Cavalli, A.; Valenti, P. Nonsteroidal aromatase inhibitors: recent advances. Med. Res. Rev. 2002, 22, 282-304.
3. Smith, H. J.; Nicholls, P. J.; Simons, C.; Le Lain, R. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin. Ther. Pat. 2001, 11, 789-824.
4. Brueggemeier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005, 26, 331-345.
5. Dixon, J. M. Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. Expert Opin. Pharmacother. 2006, 7, 2465-2479.
6. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J. F.; Hoctin-Boes, G.; Houghton, I.; Locker, G. Y.; Tobias, J. S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
7. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353, 2747-2757.
8. Coombes, R. C.; Hall, E.; Gibson, L. J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S. E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A. S.; Bajetta, E.; Dodwell, D.; Coleman, R. E.; Fallowneld, L. J.; Mickiewicz, E.; Andersen, J.; Lonning, P. E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C. F.; Carpentieri, M.; Massimini, G.; Bliss, J. M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004, 350, 1081-1092.
9. Haynes, B. P.; Dowsett, M.; Miller, W. R.; Dixon, J. M.; Bhatnagar, A. S. The pharmacology of letrozole. J. Steroid Biocrem. Mol. Biol. 2003, 87, 35-45.
10. Monnier, A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev. Anticancer Ther. 2006, 6, 1355-1359.
11. Santner, S. J.; Feil, P. D.; Santen, R. J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 1984, 59, 29-33.
12. 5-steroids in the Zr-75-1 human breast cancer cell line. Cancer Res. 1986, 46, 4933-4937.
13. Dauvois, S.; Labrie, F. Androstenedione and androst-5-ene-3β, 17β-diol stimulate DMBA-induced rat mammary tumors: role of aromatase. Breast Cancer Res. Treat. 1989, 13, 61-69.
14. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37, 219-221.
15. Woo, L. W. L.; Howarth, N. M.; Purohit, A.; Hejaz, H. A. M.; Reed, M. J.; Potter, B. V. L. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. 1998, 41, 1068-1083.
16. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev. 2005, 26, 171-202.
17. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, B. V. L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. 2000, 7, 773-791.
18. Malini, B.; Purohit, A.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 2000, 75, 253-258.
19. Purohit, A.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res. 2000, 60, 3394-3396.
20. Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; Wilson, R. H.; Stanczyk, F. Z.; Dobbs, N.; Kulinskaya, E.; Elliott, M.; Potter, B. V. L.; Reed, M. J.; Coombes, R. C. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12, 1585-1592.
21. Woo, L. W. L.; Sutcliffe, O. B.; Bubert, C.; Grasso, A.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2003, 46, 3193-3196.
22. Woo, L. W. L.; Bubert, C.; Sutcliffe, O. B.; Smith, A.; Chander, S. K.; Mahon, M. F.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2007, 50, 3540-3560.
23. Wood, P. M.; Woo, L. W. L.; Humphreys, A.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J. Steroid Biochem. Mol. Biol. 2005, 94, 123-130.
24. Jackson, T.; Woo, L. W. L.; Trusselle, M. N.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. Org. Biomol. Chem. 2007, 5, 2940-2952.
25. Numazawa, M.; Tominaga, T.; Watari, Y.; Tada, Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006, 71, 371-379.
26. Numazawa, M.; Ando, M.; Watari, Y.; Tominaga, T.; Hayata, Y.; Yoshimura, A. Structure-activity relationships of 2-, 4-, or 6-substituted estrogens as aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 2005, 96, 51-58.
27. Hejaz, H. A. M.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. Bioorg. Med. Chem. 2004, 12, 2759-2772.
28. Nussbaumer, P.; Bilban, M.; Billich, A. 4,4′-Benzophenone-O, O′-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg. Med. Chem. Lett. 2002, 12, 2093-2095.
29. Bowman, R. M.; Steele, R. E.; Browne, L. U.S. Patent 4,978,672, 1990.
30. Wittig, G.; Gauss, W. Über die verzögerte autoxydation des benzaldehyds in gegenwart von asymm. diaryl-äthylenen. Chem. Ber. 1947, 80, 363-375.
31. Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett. 2000, 41, 7047-7051.
32. Van der Mey, M.; Hatzelmann, A.; Van Klink, G. P. M.; Van der Laan, I. J.; Sterk, G. J.; Thibaut, U.; Ulrich, W. R.; Timmerman, H. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. J. Med. Chem. 2001, 44, 2523-2535.
33. Leigh, W. J.; Arnold, D. R.; Humphreys, R. W. R.; Po, C. W. Merostabilization in radical ions, triplets, and biradicals. 4. Substituent effects on the half-wave reduction potentials and n,π* triplet energies of aromatic ketones. Can. J. Chem. 1980, 58, 2537-2549.
34. Duplais, C.; Bures, F.; Sapountzis, I.; Korn, T. J.; Cahiez, G.; Knochel, P. An efficient synthesis of diaryl ketones by iron-catalyzed arylation of aroyl cyanides. Angew. Chem., Int. Ed. 2004, 43, 2968-2970.
35. Furet, P.; Batzl, C.; Bhatnagar, A.; Francotte, E.; Rihs, G.; Lang, M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J. Med. Chem. 1993, 36, 1393-1400.
36. Danel, C.; Foulon, C.; Guelzim, A.; Park, C. H.; Bonte, J. P.; Vaccher, C. Preparative enantiomeric separation of new aromatase inhibitors by HPLC on polysaccharide-based chiral stationary phases: determination of enantiomeric purity and assignment of absolute stereochemistry by X-ray structure analysis. Chirality 2005, 17, 600-607.
37. Aboul-Enein, H. Y.; Ali, I.; Gubitz, G.; Simons, C.; Nicholls, P. J. HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and amylose-based chiral stationary phases under reversed phase mode. Chirality 2000, 12, 727-733.
38. Danel, C.; Foulon, C.; Goossens, J. F.; Bonte, J. P.; Vaccher, C. Kinetics of racemization of enantiopure N-imidazole derivatives, aromatase inhibitors: studies in organic, aqueous, and biomimetic media. Tetrahedron: Asymmetry 2006, 17, 2317-2321.
39. Chiral Technologies Europe. Personal Communication.
40. Stephens, P. J.; Ashvar, C. S.; Devlin, F. J.; Cheeseman, J. R.; Frisch, M. J. Ab initio calculation of atomic axial tensors and vibrational rotational strengths using density functional theory. Mol. Phys. 1996, 89, 579-594.
41. Freedman, T. B.; Cao, X. L.; Dukor, R. K.; Nafie, L. A. Absolute configuration determination of chiral molecules in the solution state using vibrational circular dichroism. Chirality 2003, 15, 743-758.
42. Polavarapu, P. L.; He, J. T. Chiral analysis using mid-IR vibrational CD spectroscopy. Anal. Chem. 2004, 76, 61A-67A.
43. Braun, M.; Hohmann, A.; Rahematpura, J.; Buhne, C.; Grimme, S. Synthesis and determination of the absolute configuration of fugomycin and desoxyfugomycin: CD spectroscopy and fungicidal activity of butenolides. Chem. - Eur. J. 2004, 10, 4584-4593.
44. Lebon, F.; Longhi, G.; Gangemi, F.; Abbate, S.; Priess, J.; Juza, M.; Bazzini, C.; Caronna, T.; Mele, A. Chiroptical properties of some monoazapentahelicenes. J. Phys. Chem. A 2004, 108, 11752-11761.
45. Devlin, F. J.; Stephens, P. J.; Besse, P. Are the absolute configurations of 2-(1-hydroxyethyl)-chromen-4-one and its 6-bromo derivative determined by X-ray crystallography correct? A vibrational circular dichroism study of their acetate derivatives. Tetrahedron: Asymmetry 2005, 16, 1557-1566.
46. Stephens, P. J.; Devlin, F. J.; Gasparrini, F.; Ciogli, A.; Spinelli, D.; Cosimelli, B. Determination of the absolute configuration of a chiral oxadiazol-3-one calcium channel blocker, resolved using chiral chromatography, via concerted density functional theory calculations of its vibrational circular dichroism, electronic circular dichroism, and optical rotation. J. Org. Chem. 2007, 72, 4707-4715.
47. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J. Med. Chem. 2005, 48, 7282-7289.
48. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision C.02; Gaussian, Inc.: Wallingford, CT, 2004.
49. Jones, C. D.; Winter, M. A.; Hirsch, K. S.; Stamm, N.; Taylor, H. M.; Holden, H. E.; Davenport, J. D.; Vonkrumkalns, E. V.; Suhr, R. G. Estrogen synthetase Inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups. J. Med. Chem. 1990, 33, 416-429.
50. Purohit, A.; Vernon, K. A.; Wagenaar Hummelinck, A. E.; Woo, L. W. L.; Hejaz, H, A. M.; Potter, B. V. L.; Reed, M. J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. 1998, 64, 269-275.
51. Reed, J. E.; Woo, L. W. L.; Robinson, J. J.; Leblond, B.; Leese, M. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 2004, 317, 169-175.
52. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase Inhibitors. J. Med. Chem. 2007, 50, 3420-3422.
53. Recanatini, M.; Bisi, A.; Cavalli, A.; Belluti, F.; Gobbi, S.; Rampa, A.; Valenti, P.; Palzer, M.; Palusczak, A.; Hartmann, R. W. A new class of nonsteroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17α-hydroxylase/C17,20-lyase. J. Med. Chem. 2001, 44, 672-680.
54. Vanden Bossche, H.; Willemsens, G.; Roels, I.; Bellens, D.; Moereels, H.; Coene, M. C.; Lejeune, L.; Lauwers, W.; Janssen, P. A. J. R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent estrogen synthesis. Biochem. Pharmacol. 1990, 40, 1707-1718.
55. Favia, A. D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimeisional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a mokcular dynamics study of heme-cysteinato cytochromes. Proteins: Struct., Funct., Bioinf. 2006, 62, 1074-1087.
56. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
57. Hernandez-Guzman, F. G.; Higashiyama, T.; Pangborn, W.; Osawa, Y.; Ghosh, D. Structure of human estrone sulfatase suggests functional roles of membrane association. J. Biol. Chem. 2003, 278, 22989-22997.
58. Warren, G. L. Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Vall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions, J. Med. Chem. 2006, 49, 5912-5931.
59. Appel, R.; Berger, G. Hydrazinsulfonsaure-amide. 1. Über das hydrazodisulfamid. Chem. Ber. 1958, 1339-1341.
60. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-tri-n-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57, 79-88.
61. SYBYL 7.3; Tripos Inc.: St. Louis, MO; 1699 South Hanley Road, St. Louis, Missouri, 63144.
62. Williams, P. A.; Cosme, J.; Ward, A.; Angova, H. C.; Vinkovic, D. M.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003, 424, 464-468.